ClinicalTrials.gg

Program

ibuzatrelvir

Also written as “PF-07817883”, “Ibuzatrelvir co-process API film coated tablet” and “Ibuzatrelvir filmcoated tablet”.

In Pfizer's pipeline, SARS-CoV-2 3CL protease inhibitor. Its studies are mostly in COVID-19, led by Pfizer.

Furthest: phase 3, since Nov 5, 202411 company-led studies, 2 open or runningNext primary completion: Sep 28, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer112 open or runningphase 3since Nov 5, 2024Oct 11, 2022Sep 28, 2027phase 3 · NCT07013474
  • Named in Pfizer’s own pipeline as ibuzatrelvir PF-07817883, phase 3, as of Nov 3, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 11, 2022First study: phase 1 study in COVID-19First studyNCT05580003 · 94 enrolled · United States, Belgium
  2. Apr 4, 2023Phase 2 study in COVID-19NCT05799495 · 240 enrolled · United States
  3. Apr 10, 2023Phase 1 study in COVID-19NCT05822440 · 12 enrolled · United States
  4. May 23, 2023Phase 1 study in COVID-19NCT05884554 · 21 enrolled · United States
  5. Oct 10, 2023Phase 1 study in HealthyNCT06122194 · 12 enrolled · Belgium
  6. Aug 1, 2024Phase 1 study in COVID-19NCT06586216 · 16 enrolled · United States
  7. Oct 15, 2024Phase 1 study in HealthyNCT06646042 · 12 enrolled · United States
  8. Nov 5, 2024Phase 3 study in Pneumonia, ViralNCT06679140 · 2,330 planned · United States, Argentina, Belgium and more
  9. May 5, 2025Phase 3 study in COVID-19NCT07013474 · 300 planned · United States, Argentina, Belgium and more
  10. Nov 14, 2025Phase 1 study in COVID-19NCT07235137 · 12 enrolled · China
  11. Apr 7, 2026Phase 1 study in COVID-19NCT07552779 · 17 enrolled · Belgium

Ahead

  1. Sep 28, 2027Primary completion: phase 3 study in COVID-19NCT07013474
  2. Oct 1, 2027Primary completion: phase 3 study in Pneumonia, ViralNCT06679140

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“SARS-CoV-2 3CL protease inhibitor”the company's pipeline, read by Claude · source
“An orally bioavailable, second-generation inhibitor of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) main protease (Mpro; 3C-like protease; 3CL protease; 3CLpro; nsp5 protease), with potential antiviral activity against SARS-CoV-2 and other coronaviruses. Upon oral administrati…”NCIt, read by Claude

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07552779COVID-19 · Belgium1CompletedJun 3, 202617
NCT07235137COVID-19 · China1CompletedNov 21, 202512
NCT07013474COVID-19 · United States, Argentina, Belgium and more3RecruitingSep 28, 2027300
NCT06679140Pneumonia, Viral · United States, Argentina, Belgium and more3RecruitingOct 1, 20272,330
NCT06646042Healthy · United States1CompletedJan 17, 202512
NCT06586216COVID-19 · United States1CompletedFeb 13, 202516
NCT06122194Healthy · Belgium1CompletedJan 12, 202412
NCT05884554COVID-19 · United States1CompletedJun 27, 202421
NCT05822440COVID-19 · United States1CompletedJul 10, 202312
NCT05799495COVID-19 · United States2CompletedSep 13, 2023240
NCT05580003COVID-19 · United States, Belgium1CompletedSep 15, 202394

How it is read

Names in the registry

  • “PF-07817883”, 5 entries
  • “ibuzatrelvir”, 3 entries
  • “Ibuzatrelvir co-process API film coated tablet”, 1 entry
  • “Ibuzatrelvir filmcoated tablet”, 1 entry
  • “Ibuzatrelvir”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.